Translate this page into:
Chronic myeloid leukemia in children and adolescents: A single center experience from Eastern India
*Corresponding author: Dr. Lalit Raut. lalitraut76@yahoo.co.in
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Context: Chronic Myeloid Leukemia (CML) constitutes around 3% of leukemia in the children and adolescent age group. Aims: The aim of the study was to evaluate the characteristics at presentation and the treatment outcome of CML in the children and adolescent age group. Settings and Design: Retrospective analysis was carried out at a single center in India. Materials and Methods: Thirteen patients (≤17 years) attending CML outdoor from April 2008 to August 2012 were included in the analysis. Statistical Analysis Used: The mean and median of various parameters were calculated using a Microsoft excel sheet. SPSS 16.0 version software was used to calculate OS and PFS. Results: CML-CP was the most common phase at presentation. Maximum patients belonged to the 14 - 17 year old age group. Disease was common in the male sex. Splenic discomfort and asthenia were the most common symptoms and splenomegaly was the most common sign. Conclusions: The treatment with Imatinib was effective and well-tolerated.
Keywords
References
- Altman AJ. Chronic leukemias of childhood. Pediatr Clin North Am 1988;35:765-87.
- Dikshit RP, Nagrani R, Yeole B, Koyande S, Banawali S. Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years. Indian J Med Paediatr Oncology 2011;32:96-100.
- Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. New Engl J Med 2003;349:1451-64.
- Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel of behalf of the European Leukemia Net. Blood 2006;108:1809-20.
- Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a children′s oncology group phase 1 study. Blood 2004;104:2655-60.
- El-Alfy MS, Al-Haddad AM, Hamed AA. Management of CML in the pediatric age group: Imatinib Mesylate or SCT. J Egypt Natl Canc Inst 2010;22:227-32.
- Hardisty RM, Speed DE, Till M. Granulocytic leukemia in childhood. Br J Haematol 1964;10:551-66.
- Castro-Malaspina H, Schaison G, Briere J, Passe S, Briere J, Pasquier A, et al. Philadelphia chromosome-positive chronic myelocytic leukemia in children. Cancer 1983;52:721-7.
- Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 2005;116:140-3.
- Ray SS, Chakrabarti P, Nath U, Chaudhuri U. A single center experience of treating CML in a tertiary care center at eastern India. 51st National Conference of Indian Society of Haematology and Transfusion Medicine 2010,18th -21st Nov 2010. Kolkata, India: Springer; 2010. p. 129-181.
- Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia in early chronic phase: Results of the French national phase IV trial. Blood 2009;114:863.
- Suttorp M, Thiede C, Tauer JT, Roettgers S, Sedlacek P, Harbott J. Chronic myeloid leukemia in pediatrics-first results from study CML-PAED II. Blood 2009;114:342.